Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
15 participants
INTERVENTIONAL
2018-06-29
2018-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis
NCT05906433
Different Kinds of Acupuncture Treatment for Knee Osteoarthritis
NCT03563690
Metformin Safety and Efficacy in Osteoarthritis.
NCT06231758
Diphenhydramine Ointment for Knee Osteoarthritis
NCT05036174
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Knee Osteoarthritis
NCT05398874
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Comarum Palustre
Patients taking Comarum Palustre together with conventional treatment for osteoarthritis
Comarum Palustre
Comarum Palustre tablets 500 mg BID, 1 month
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Comarum Palustre
Comarum Palustre tablets 500 mg BID, 1 month
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of type 2 diabetes mellitus
Exclusion Criteria
* pregnancy and lactation
* increased sensitivity to the study drug
* clinically significant renal function impairment
* use of antidepressants
* diagnosis of bipolar disorder
* use of symptomatic slow acting drugs of OA (SYSADOA) one month prior to study entry
* any condition which may lead to difficulties to participation in the study from the viewpoint of Investigator
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ivan Shirinsky, MD, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ivan Shirinsky
Role: PRINCIPAL_INVESTIGATOR
Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratory of Clinical Immunopharmacology
Novosibirsk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LCI001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.